EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance

Lucia Mráziková, Silvie Hojná, Petra Vaculová, Štěpán Strnad iD, Vladimír Vrkoslav iD, Helena Pelantová iD, Marek Kuzma, Blanka Železná, Jaroslav Kuneš, Lenka Maletínská

Nutrients · 2023

DOI: 10.3390/nu15020280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Lucia Mráziková und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, 160 00 Prague, Czech Republic. Hauptthemen laut MEDLINE: Glucose Intolerance, Insulin Resistance, Prediabetic State. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Czech Science Foundation, European Union - Next Generation EU, National Institute for Research on Cardiovascular Diseases Related to Metabolic Diseases of Diabetes and Obesity.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prolactin-releasing peptide (PrRP) is an anorexigenic neuropeptide that has potential for the treatment of obesity and its complications. Recently, we designed a palmitoylated PrRP31 analog (palm11-PrRP31) that is more stable than the natural peptide and able to act centrally after peripheral administration. This analog acted as an anti-obesity and glucose-lowering agent, attenuating lipogenesis in rats and mice with high-fat (HF) diet-induced obesity. In Wistar Kyoto (WKY) rats fed a HF diet for 52 weeks, we explored glucose intolerance, but also prediabetes, liver steatosis and insulin resistance-related changes, as well as neuroinflammation in the brain. A potential beneficial effect of 6 weeks of treatment with palm11-PrRP31 and liraglutide as comparator was investigated. Liver lipid profiles, as well as urinary and plasma metabolomic profiles, were measured by lipidomics and metabolomics, respectively. Old obese WKY rats showed robust glucose intolerance that was attenuated by palm11-PrRP31, but not by liraglutide treatment. On the contrary, liraglutide had a beneficial effect on insulin resistance parameters. Despite obesity and prediabetes, WKY rats did not develop steatosis owing to HF diet feeding, even though liver lipogenesis was enhanced. Plasma triglycerides and cholesterol were not increased by HFD feeding, which points to unincreased lipid transport from the liver. The liver lipid profile was significantly altered by a HF diet that remained unaffected by palm11-PrRP31 or liraglutide treatment. The HF-diet-fed WKY rats revealed astrogliosis in the brain cortex and hippocampus, which was attenuated by treatment. In conclusion, this study suggested multiple beneficial anti-obesity-related effects of palm11-PrRP31 and liraglutide in both the periphery and brain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucose IntoleranceInsulin ResistancePrediabetic StateRatsMiceAnimalsRats, Inbred WKYHypoglycemic AgentsLiraglutideProlactin-Releasing HormoneObesityLipidsDiet, High-Fat

Stichwörter der Autor:innen

Wistar Kyoto ratsastrocytosisdiet-induced obesityglucose intolerancelipid metabolismlipidomicsliraglutidemetabolomicsprolactin-releasing peptide

Substanzen

Hypoglycemic AgentsLiraglutideProlactin-Releasing HormoneLipids

Autor:innen und Institutionen

  • Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, 160 00 Prague, Czech Republic.
  • Institute of Physiology, Czech Academy of Sciences, 142 20 Prague, Czech Republic.
  • Institute of Microbiology, Czech Academy of Sciences, 142 20 Prague, Czech Republic.

ORCID-Profile: Štěpán Strnad, Vladimír Vrkoslav, Helena Pelantová

Förderung

  • Czech Science Foundation
  • European Union - Next Generation EU
  • National Institute for Research on Cardiovascular Diseases Related to Metabolic Diseases of Diabetes and Obesity
  • European Union—Next Generation EU

Zitieren

APA

Mráziková, L., Hojná, S., Vaculová, P., Strnad, Š., Vrkoslav, V., Pelantová, H., Kuzma, M., Železná, B., Kuneš, J., & Maletínská, L. (2023). Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance. Nutrients. https://doi.org/10.3390/nu15020280

Vancouver

Mráziková L, Hojná S, Vaculová P, Strnad Š, Vrkoslav V, Pelantová H, et al. Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance. Nutrients. 2023. doi:10.3390/nu15020280

BibTeX
@article{Mrzikov2023,
  author = {Mráziková, Lucia and Hojná, Silvie and Vaculová, Petra and Strnad, Štěpán and Vrkoslav, Vladimír and Pelantová, Helena and Kuzma, Marek and Železná, Blanka and Kuneš, Jaroslav and Maletínská, Lenka},
  title = {Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15020280}
}
Kostenlos starten →